DP1 Agonist | Route | Dose | Species | Experimental Model | Indication | Reference |
---|---|---|---|---|---|---|
572C85 192C86 | Topical | 2–250 μg | Rabbit, cat | Intraocular pressure | Glaucoma | Matsugi et al., 1995 |
AL-6598 | Topical | 0.01% | Monkey | Intraocular pressure | Glaucoma | Toris et al., 2006 |
BW 245C | Intrathecal | 83 ng/kg (IC50) | Mouse | Nociceptin-induced allodynia | Chronic pain | Minami et al., 1997 |
BW 245C | Topical | 2.5 μg | Rabbit | Intraocular pressure | Glaucoma | Goh et al., 1988 |
BW 245C | Topical | 50 μM | Mouse | Epicutaneous sensitization to OVA | Atopic dermatitis | Angeli et al., 2004 |
BW 245C | Intratracheal | 100 μM | Mouse | OVA-alum asthma | Asthma | Hammad et al., 2007 |
BW 245C | 1–1000 nM | Rat | Cell/tissue culture | Neurodegenerative diseases | Liang et al., 2005b | |
BW 245C | In vitro+ (−/− DP1 mice) | 0.05–5 μM | Mouse | Ischemia-reperfusion injury | Cerebral ischemic disorders | Saleem et al., 2007b |
BW 245C | Topical | 0.01–1% | Rabbit | Intraocular pressure | Glaucoma | Woodward et al., 1990 |
BW 245C AS 702224 | Intracavernosal | BW 245C, 59 nM; AS 702224, 29 nM (EC50 in isolated human tissue) | Rabbit, rat, human cavernosal tissue | Penile tumescence | Erectile dysfunction | Brugger et al., 2008 |
SQ-27986 | Topical | 2.5–25 μg | Rabbit | Intraocular pressure | Glaucoma | Woodward et al., 1993 |
SQ-27986 | Topical | 1–30 μg | Monkey | Intraocular pressure | Glaucoma | Crawford et al., 1992 |
TS-022 | Topical | 2.5 → 250 nM | Mouse | NC/Nga mice | Atopic dermatitis | Arai et al., 2007 |
AL-6598, 2-[[(2Z)-4-[(1R,2R,3R,5R)-5-chloro-2-[(3R)-3-cyclohexyl-3- hydroxypropyl]-3-hydroxycyclopentyl]-2-buten-1-yl]oxy]-1-methylethyl ester, acetic acid.